Cargando…

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, P. J., Chng, W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/
https://www.ncbi.nlm.nih.gov/pubmed/25028664
http://dx.doi.org/10.1155/2014/717919
_version_ 1782324411223769088
author Teoh, P. J.
Chng, W. J.
author_facet Teoh, P. J.
Chng, W. J.
author_sort Teoh, P. J.
collection PubMed
description p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma.
format Online
Article
Text
id pubmed-4083709
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40837092014-07-15 p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma Teoh, P. J. Chng, W. J. Biomed Res Int Review Article p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma. Hindawi Publishing Corporation 2014 2014-06-17 /pmc/articles/PMC4083709/ /pubmed/25028664 http://dx.doi.org/10.1155/2014/717919 Text en Copyright © 2014 P. J. Teoh and W. J. Chng. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Teoh, P. J.
Chng, W. J.
p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
title p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
title_full p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
title_fullStr p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
title_full_unstemmed p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
title_short p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
title_sort p53 abnormalities and potential therapeutic targeting in multiple myeloma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/
https://www.ncbi.nlm.nih.gov/pubmed/25028664
http://dx.doi.org/10.1155/2014/717919
work_keys_str_mv AT teohpj p53abnormalitiesandpotentialtherapeutictargetinginmultiplemyeloma
AT chngwj p53abnormalitiesandpotentialtherapeutictargetinginmultiplemyeloma